http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2422141-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5a6907c0df7c11e72803b375909e45fc http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e9494c30f8f6cb9e15dc21e0d6895855 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-426 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61H1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-401 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 |
| filingDate | 2010-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ffef836579578b50a5fb4d436cdaa63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7fba409fd58742cc3f13f55ce548eba1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2395b85fd481b1e436fe87495a82cb1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d1d9836ddcc9f8430d9b05cc3a53676 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3f0bff1c920c3eaf780643495ef04de |
| publicationDate | 2011-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2422141-C1 |
| titleOfInvention | Method of normalisation of functional activity of vessel wall in patients with arterial hypertension of i-ii degree with metabolic syndrome, after thrombosis of eye vessels |
| abstract | FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to cardiology and angiology, and deals with normalisation of functional activity of vessel wall in patients with arterial hypertension of I-II degree with metabolic syndrome, after thrombosis of eye vessels. For this purpose, indices of anti-aggregation, anti-coagulation and fibrinolytic activity of vascular wall are determined. On the basis of said indices general anti-thrombotic potential of vessels is calculated and if its value is 0.069 and lower, administered is complex treatment, including application of individually selected hupocaloric diet, dosed physical load, introduction of pioglitazone in dose 30 mg 1 time per day and lisinopril in dose 20 mg 1 time per day for 4 months. ^ EFFECT: complex of drug and non-drug therapy in combination with empirically selected treatment duration ensures complete normalisation of functional activity of vascular wall and, thus, reduction of risk of thrombotic complications in said group of patients due to potentiation of therapeutic effect of separate components of medicinal complex. ^ 2 ex, 1 dwg |
| priorityDate | 2010-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 64.